Download Image
    
Share
  
Post
Inhaled Heparin for COVID-19
3 studies with 493 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Inhaled Heparin
Significantly lower risk for mortality, ventilation, and hospitalization.
One study shows significant benefit.
COVID-19 Inhaled Heparin studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 50% Mortality 50% Hospitalization 19% RCTs 50% RCT mortality 50% Late 50% Favorsinhaled heparin Favorscontrol
Inhaled nebulized unfractionated heparin shows antiviral, anti-inflammatory, and anti-coagulant effects which may minimize viral entry, progression of lung injury, and pulmonary thrombosis. Recent:
DeNucci
Smith
van Haren.
Nov 25
 Covid Analysis Inhaled Heparin reduces COVID-19 risk: real-time meta analysis of 3 studies
Significantly lower risk is seen for mortality, ventilation, and hospitalization. One study shows significant benefit. Meta analysis using the most serious outcome reported shows 50% [17‑70%] lower risk. Currently all studies a..
Oct 31
 van Haren et al., eClinicalMedicine, doi:10.1016/j.eclinm.2025.103339 Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an investigator-initiated international meta-trial of randomised clinical studies
58% lower mortality (p=0.01), 47% lower ventilation (p=0.01), and 23% lower hospitalization (p=0.02). Meta-trial of 6 RCTs with 478 hospitalized COVID-19 patients showing significant benefit with inhaled nebulized unfractionated heparin (UFH). Patients receiving nebulized UFH had lower rates of intubation or death at longest follow-up (11..
Mar 27
 Smith et al., Anaesthesia and Intensive Care, doi:10.1177/0310057X251322783 A randomised, open-label trial of nebulised unfractionated heparin in patients mechanically ventilated for COVID-19
70% higher mortality (p=1). RCT 50 intubated COVID-19 patients showing no improvement with inhaled nebulized unfractionated heparin. Time to separation from invasive ventilation among survivors to day 28 was significantly slower in the heparin group.
Jun 30
2023
 DeNucci et al., Pulmonary Pharmacology & Therapeutics, doi:10.1016/j.pupt.2023.102212 Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study
42% lower mortality (p=0.27), 42% lower ventilation (p=0.27), and 5% shorter hospitalization (p=0.8). RCT 75 hospitalized patients with COVID-19 showing reduced mortality with inhaled nebulized unfractionated heparin (UFH).